# Nina Gotcheva

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nina-gotcheva/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,635 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 28 |
| i10-index | 39 |
| OpenAlex ID | https://openalex.org/A5064284791 |
| ORCID iD | https://orcid.org/0000-0003-2787-6283 |
| Works | 82 |

## Researcher papers

- [ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)](https://scholariq.org/papers/esc-eas-guidelines-for-the-management-of-dyslipidaemias-the-task-force-for-the/)
- [2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy](https://scholariq.org/papers/2018-esc-guidelines-for-the-management-of-cardiovascular-diseases-during/)
- [ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)](https://scholariq.org/papers/esc-guidelines-on-the-management-of-cardiovascular-diseases-during-pregnancy-the/)
- [2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes](https://scholariq.org/papers/2023-esc-guidelines-for-the-management-of-cardiovascular-disease-in-patients/)
- [Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-interleukin-1-inhibition-with-canakinumab-on-incident-lung-cancer-in/)
- [EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries](https://scholariq.org/papers/euroaspire-iv-a-european-society-of-cardiology-survey-on-the-lifestyle-risk/)
- [Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry](https://scholariq.org/papers/lifestyle-and-impact-on-cardiovascular-risk-factor-control-in-coronary-patients/)
- [Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial](https://scholariq.org/papers/relationship-of-c-reactive-protein-reduction-to-cardiovascular-event-reduction/)
- [Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries](https://scholariq.org/papers/management-of-dyslipidaemia-in-patients-with-coronary-heart-disease-results-from/)
- [Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial](https://scholariq.org/papers/effects-of-alirocumab-on-cardiovascular-and-metabolic-outcomes-after-acute/)
- [Empagliflozin after Acute Myocardial Infarction](https://scholariq.org/papers/empagliflozin-after-acute-myocardial-infarction/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Cardiac Health and Mental Health](https://scholariq.org/topics/cardiac-health-and-mental-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.